Evaluation of adverse events triggered by the use of chloroquine diphosphate, emphasis on retina toxicity, in 350 patients with lupus erythematosus;PP04 - Avaliação dos efeitos adversos desencadeados pelo uso de difosfato de cloroquina, com ênfase na retinotoxicidade, em 350 doentes com lúpus eritematoso

Anais Brasileiros de Dermatologia

Volumn 80, Issue SUPPL. 3, 2005, Pages

  Ponchet, Maria Raquel Nogueira C ^a,b   Vilela, Maria Apparecida C ^a   Suni Sinahara, Karen Krist ^a   De Freitas Dotto, Patrícia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b USP ^*  (Brazil)

Author keywords

Chloroquine adverse effects; Lupus erythematosus, cutaneous therapy; Macular degeneration chemically induced

Indexed keywords

CHLOROQUINE;

ADULT; AGED; CONFERENCE PAPER; CONTROLLED STUDY; CORNEA DISEASE; DISEASE CLASSIFICATION; EYE TOXICITY; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LUPUS ERYTHEMATOSUS; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MEDICAL RECORD; MENTAL DISEASE; NEUROMUSCULAR DISEASE; PERIODICITY; RETINOPATHY; SCREENING TEST; SKIN DISEASE; VISUAL DISORDER;

EID: 33846811422     PISSN: 03650596     EISSN: 18064841     Source Type: Journal    
DOI: 10.1590/s0365-05962005001000003     Document Type: Conference Paper

References (30)

1. Wallace DJ. Antimalarial agents and lupus. Rheum Dis Clin North Am. 1994;20:243-63.
2. Meinäo IM, Sato EI, Andrade LEG, Ferraz MB, Atra E. Controled trial with chloroquine diphosphate in systemic lupus erythematosus. Lupus. 1996;5:237-4l.
3. Easterbrook M. An ophthalmological view on the efficacy and safety of chloroquine versus hydroxychloroquine. J Rheumatol. 1999;26:1866-8.
4. Hobbs HE, Sorsby A, Friedman A. Retinopathy following chloroquine therapy. Lancet. 1959;2:478-80.
5. Finbloom DS, Silver K, Newsome DA, Gunkel R. Comparison of hydroxichloroquine and chloroquine use and the development of retinal toxicity. J Rheumatol. 1985;12:692-4.
6. Henkind P, Carr RE, Siegel IM. Early chloroquine retinopathy. Clinical and functional findings. Arch Ophthalmol. 1964;71:157-65.
7. Dubois EL, Shearer RV. Ocular changes induced by long-term hydroxychloroquine (plaquenil) therapy. Am J Ophthalmol. 1967;64:245-52.
8. Marmor MF, Carr RE, Easterbrook M, Farjo AA, Mieler WF. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy. Am Acad Ophthalmol. 2002;109:1377-82.
9. Mackenzie AH. Dose refinements in long-term therapy of rheumatoid arthritis with antimalarials. Am J Med. 1983;18:40-5.
10. Bernstein HN. Ocular safety of hydroxychloroquine sulfate (plaquenil). South Med J. 1992;85:274-9.
11. Easterbrook M. Detection and prevention of maculopathy associated with antimalarial agents. Int Ophthalmol Clin. 1999;39:49-57.
12. Aviña-Zubieta JA, Rodriguez GG, Newman S, Almazor MES, Russell AS. Long term effectiveness of antimalarial drugs in rheumatic diseases. Ann Rheum Dis. 1998; 57:582-7.
13. Rynes RI. Antimalarial drugs in the treatment of rheumatological diseases. Br J Rheumatol. 1997;36:799-805.
14. Rockwell DA. Psychiatric complications with chloroquine and quinacrine. Am J Psychiatry. 1968;124:1257-60.
15. Taylor WRJ, White NJ. Antimalarial Drug Toxicity: a review. Drug Saf. 2004;27:25-61.
16. Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol. 1964;80:407-12.
17. Klinger G, Morad Y. Ocular toxicity and antenatal exposure to chloroquine or hidroxychloroquine for rheumatic diseases. Lancet. 2001;358:813-4.
18. Borba EF, Turrini-Filho JR, Kuruma KAM, Bertola C, Pedalini MEB, Lorenzi MC, et al. Chloroquine gestational use in systemic lupus erythematosus:assessing the risk of child ototoxicity by pure tone audiometry. Lupus. 2004;13:223-7.
19. Sontheimer RD. The lexicon of cutaneous lupus erythematosus - A review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus. 1997;6:84-95.
20. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.
21. Nylander U. Ocular damage in chloroquine therapy. Acta Ophthalmol. 1967;92:1-71.
22. Ikehara W, Andrade MS, Latorre LC, Zerbini CAF. Retinopatia em pacientes usando difosfato de cloroquina na artrite reumatóide. Rev Bras Reumatol. 2001;4l:53-8.
23. Smith JL. Chloroquine macular degeneration. Arch Ophthalmol. 1962;68:186-70.
24. Portnov JZ, Callen JP. Ophthamologic aspects of chloroquine and hydroxychloroquine therapy. Int J Dermatol. 1983;22:273-8.
25. Percival SPB, Behrman J. Ophthalmological safety of chloroquine. Br J Ophthalmol. 1969;53:101-9.
26. Isaacson D, Elgart M, Turner ML. Antimalarials in dermatology. Int J Dermatol. 1982;21:379-95.
27. Scherbel AL, Mackenzie A, Nousek JE, Atdjian M. Ocular lesions in rheumatoid arthritis and related disorders with particular reference to retinophaty: A study of 741 patients treated with and without chloroquine drugs. N Engl J Med. 1965;273:360-6.
28. Koranda FC. Antimalarials. J Am Acad Dermatol. 1981;4:650-5.
29. Kornzweig AL. The eye in old age. Diseases of the macula: a clinic pathologic study. Am J Ophthalmol. 1965;60:835-43.
30. Elman A, Gullbergr R, Nilsson E, Rendahl I, Wachtmeister L. Chloroquine retinopathy in patients with rheumatoid arthritis. Scand J Rheumatol. 1976;5:161-6.